XLIFE-SCIENCES-AG
23.12.2020 11:16:15 CET | Business Wire | Press release
Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a part of the Board of Directors of Veraxa as a minority shareholder. Veraxa Biotech AG is positioned as a leading provider in the identification and development of functional antibodies and drug conjugates.
Xlife Sciences AG will exceed its earnings expectations for 2020 with this first completed transaction since founding of the company. Araxa Biosciences GmbH was a spin-off from the European Molecular Biology Laboratory EMBL in Heidelberg and was founded by Xlife Sciences AG in summer 2019. Over the past one and a half years, Xlife has invested nearly one million euros in the company. In collaboration with various industry experts, the technological development of Araxa has been successfully advanced.
About Veraxa Biotech AG
Veraxa Biotech AG identifies and develops functional antibodies and antibody drug conjugates (ADC's) for the bio- and pharmaceutical industry in exchange for license agreements. The aim is to accelerate the safe development of medical drugs, as well as to enhance the probabilities of drug developments in various clinical phases. Using this technology, Veraxa Biotech AG can screen millions of b-cells in one single step in less than 48 hours for functional antibodies and additionally also modify them with drug conjugates.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005137/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor Secures Permanent Injunction in India Following Rulings in Europe and the United States12.8.2026 15:00:00 CEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ: 046890, hereinafter 'Seoul') and its affiliate Seoul Viosys Co., Ltd. (KOSDAQ: 092190), global opto-semiconductor technology companies, have obtained a permanent injunction enjoining infringement of Seoul’s opto-semiconductor patents in India, following similar injunction rulings in Europe and the United States. The Delhi High Court extended the injunction to the managing director as well. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812490873/en/ Patented opto-semiconductor light-output enhancement technology applied in the lawsuits (left) and WICOP technology (right) (Graphic: Seoul Viosys) These rulings are expected to significantly impact the global opto-semiconductor industry, a market worth roughly USD 200 billion that is expanding from automotive lighting and displays into optical communications for AI applications. In India, Seoul Viosys won a final judgment against Ornate
Rimini Street Expands C-Suite Leadership for Growth with Appointment of Two Proven Industry Veterans as Chief Operating Officer and Chief Delivery Officer12.8.2026 15:00:00 CEST | Press release
Rimini Street appoints Keith Costello as EVP and Chief Operating Officer and Alexander Guasch as EVP and Chief Delivery Officer Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced the appointment of Keith Costello as chief operating officer (COO) and Alexander Guasch as chief delivery officer (CDO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812127732/en/ Rimini Street Expands C-Suite Leadership for Growth with Appointment of Two Proven Industry Veterans as Chief Operating Officer and Chief Delivery Officer New COO Brings Proven Experience Scaling Organizations for Growth Keith Costello brings decades of experience building and scaling global enterprise software and services organizations, including leading teams of tens of thousands and managing businesses generating billions of dollars i
Brightfin Helps Federal Agencies Plan IT Finances Faster and Cut Telecom Costs Through Knox’s FedRAMP Platform12.8.2026 15:00:00 CEST | Press release
Partnership gives government organizations a compliant path to faster financial planning, more strategic decision-making, operational efficiency, and lower IT and telecom costs Brightfin today announced that its technology spend management solutions are now available to U.S. federal agencies through Knox’s FedRAMP Authorized cloud platform. Deploying on Knox gives public sector organizations a compliant path to faster financial planning cycles, more strategic decision-making, and lower IT and telecom costs, the same discipline commercial enterprises rely on. Brightfin is actively working with Knox toward achieving FedRAMP certification. Federal agencies have long struggled with IT spend data that is siloed and disconnected, limiting their ability to manage hardware and software assets and their associated costs. The result is a reactive posture, scrambling to keep pace with evolving government requirements rather than getting ahead of them. Built natively on ServiceNow, Brightfin turns
illumynt Appoints Matt Popieniuck as Vice President of Customer Success & Delivery12.8.2026 14:00:00 CEST | Press release
28-year Dell Technologies veteran, most recently leading services sustainability strategy, joins to own end-to-end program execution as illumynt scales its AI hardware lifecycle business illumynt, a technology-driven leader in AI hardware lifecycle recovery and IT asset disposition (ITAD), today announced that Matt Popieniuck has joined the company as Vice President of Customer Success & Delivery, effective August 2026. He reports to CEO Jörg Herbarth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812482293/en/ Matthew Popieniuck, Vice President of Customer Success and Delivery. Popieniuck joins illumynt after 28 years at Dell Technologies, where he progressed from group leadership through senior and principal program management roles before moving into services sustainability strategy. In that most recent chapter, he worked on the question now driving illumynt's market: what happens to enterprise technology after its fi
Ant Group launches AQ for Doctor, bringing an AI-powered workstation to millions of physicians12.8.2026 13:44:00 CEST | Press release
Ant Group today officially upgraded its physician platform, Haodf for Doctor, into AQ for Doctor, an AI-powered workstation designed to support physicians across every stage of clinical practice—from online consultations and patient management to clinical decision support and medical research. The platform is fully integrated with Ant Group's flagship AI health app, AQ, which serves more than 100 million users as of August 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812917154/en/ Ant Group launches AQ for Doctor, bringing an AI-powered workstation to millions of physicians. Connecting doctors and patients through one AI platform "AI will never replace doctors," said Zhang Junjie, Vice President of Ant Group and Head of the Health Business. "But AI can become a trusted assistant for healthcare professionals. Our goal is to build a reliable and practical AI workstation for China's more than five million physicians—
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom